Jacqueline E. Shea's most recent trade in Inovio Pharmaceuticals Inc was a trade of 105,262 Common Stock Option done . Disclosure was reported to the exchange on May 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 105,262 | 105,262 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 84,888 | 84,888 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 17,744 | 67,402 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 17,744 | 17,744 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.95 per share. | 15 May 2025 | 7,717 | 59,685 (0%) | 0% | 1.9 | 15,048 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2025 | 5,500 | 52,050 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2025 | 5,500 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.80 per share. | 10 May 2025 | 2,392 | 49,658 (0%) | 0% | 1.8 | 4,306 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 105,649 | 105,649 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 85,201 | 85,201 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 18,632 | 55,638 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 18,632 | 37,263 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.98 per share. | 26 Feb 2025 | 9,088 | 46,550 (0%) | 0% | 2.0 | 17,994 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,852 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,852 | 39,499 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.98 per share. | 26 Feb 2025 | 2,493 | 37,006 (0%) | 0% | 2.0 | 4,936 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 17,745 | 35,488 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 17,745 | 41,365 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.07 per share. | 15 May 2024 | 7,718 | 33,647 (0%) | 0% | 13.1 | 100,874 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2024 | 5,500 | 26,012 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2024 | 5,500 | 5,500 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.65 per share. | 10 May 2024 | 2,392 | 23,620 (0%) | 0% | 10.7 | 25,475 | Common Stock |
| Inovio Pharmaceuticals Inc | E. Jacqueline Shea | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 69,733 | 69,733 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Shea Jacqueline E. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 55,895 | 55,895 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Shea E. Jacqueline | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 5,853 | 23,368 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | E. Jacqueline Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 5,853 | 5,852 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Shea Jacqueline E. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.16 per share. | 26 Feb 2024 | 2,856 | 20,512 (0%) | 0% | 8.2 | 23,305 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline Shea E. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 1,878 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | E. Jacqueline Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 1,878 | 18,387 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | E. Shea Jacqueline | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.16 per share. | 26 Feb 2024 | 872 | 17,515 (0%) | 0% | 8.2 | 7,116 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 638,800 | 638,800 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2023 | 66,000 | 226,817 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2023 | 66,000 | 132,000 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.81 per share. | 10 May 2023 | 28,704 | 198,113 (0%) | 0% | 0.8 | 23,250 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2023 | 59,737 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2023 | 59,737 | 186,797 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 11 Mar 2023 | 25,980 | 160,817 (0%) | 0% | 1.1 | 29,357 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2023 | 836,800 | 836,800 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2023 | 70,234 | 140,466 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2023 | 70,234 | 159,545 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.28 per share. | 26 Feb 2023 | 32,485 | 127,060 (0%) | 0% | 1.3 | 41,581 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2023 | 22,544 | 99,099 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2023 | 22,544 | 22,544 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.28 per share. | 26 Feb 2023 | 9,788 | 89,311 (0%) | 0% | 1.3 | 12,529 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 309,400 | 309,400 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 198,000 | 198,000 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2022 | 16,666 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2022 | 16,666 | 83,802 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.63 per share. | 25 Mar 2022 | 7,247 | 76,555 (0%) | 0% | 3.6 | 26,307 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2022 | 59,737 | 93,110 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2022 | 59,737 | 59,737 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.22 per share. | 11 Mar 2022 | 25,974 | 67,136 (0%) | 0% | 3.2 | 83,636 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2022 | 282,300 | 282,300 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2022 | 210,700 | 210,700 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2022 | 22,545 | 45,088 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2022 | 22,545 | 44,137 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.22 per share. | 26 Feb 2022 | 10,764 | 33,373 (0%) | 0% | 3.2 | 34,660 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.01 per share. | 09 Jun 2021 | 38,535 | 21,592 (0%) | 0% | 10.0 | 385,735 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 16,667 | 16,666 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 16,667 | 72,084 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.06 per share. | 25 Mar 2021 | 7,247 | 64,837 (0%) | 0% | 9.1 | 65,658 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.97 per share. | 25 Mar 2021 | 4,710 | 60,127 (0%) | 0% | 9.0 | 42,249 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2021 | 59,737 | 98,272 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2021 | 59,737 | 119,474 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.57 per share. | 11 Mar 2021 | 25,974 | 72,298 (0%) | 0% | 10.6 | 274,545 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.06 per share. | 11 Mar 2021 | 16,881 | 55,417 (0%) | 0% | 10.1 | 169,823 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 104,833 | 104,833 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 67,633 | 67,633 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 15.06 per share. | 01 Feb 2021 | 22,376 | 44,495 (0%) | 0% | 15.1 | 336,983 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 22,376 | 100,000 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.62 per share. | 01 Feb 2021 | 22,376 | 66,871 (0%) | 0% | 3.6 | 81,001 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 01 Feb 2021 | 5,960 | 38,535 (0%) | 0% | 15 | 89,400 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 55,248 | 122,376 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.62 per share. | 27 Jan 2021 | 55,248 | 61,208 (0%) | 0% | 3.6 | 199,998 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 27 Jan 2021 | 22,376 | 11,920 (0%) | 0% | 12.0 | 268,736 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 22,376 | 177,624 | - | - | Common Stock Option | |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.62 per share. | 27 Jan 2021 | 22,376 | 34,296 (0%) | 0% | 3.6 | 81,001 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 12.04 per share. | 27 Jan 2021 | 16,713 | 44,495 (0%) | 0% | 12.0 | 201,225 | Common Stock |
| Inovio Pharmaceuticals Inc | Jacqueline E. Shea | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 12.04 per share. | 27 Jan 2021 | 5,960 | 5,960 (0%) | 0% | 12.0 | 71,758 | Common Stock |